ArticleFrontiers in immunology2026
Pan-cancer analysis of OSR2 with a focus on underlying mechanisms and therapeutic implications in lung adenocarcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The transcription factor Odd-skipped related 2 (OSR2) is involved in multiple physiological processes, yet its role in cancer pathogenesis remains largely undefined. Preliminary studies have suggested that OSR2 may contribute to the invasion and metastasis of several solid tumors. However, its function in the tumor microenvironment, its prognostic value and potential in predicting responses to immunotherapy across different cancer types are still inadequately explored and warrant a comprehensive systematic analysis. Methods: We performed an integrated pan-cancer analysis of OSR2 utilizing data from TCGA and GEO. Our analysis systematically evaluated OSR2 expression patterns, prognostic significance, and its correlations with tumor mutational burden (TMB), microsatellite instability (MSI), immune infiltration and immune checkpoint gene expression. Gene set enrichment analysis was employed for pathway enrichment analysis in both the pan-cancer bulk RNA-seq and LUAD single-cell transcriptomic data. The functional roles of OSR2 in LUAD were further validated through Results: OSR2 expression exhibited considerable heterogeneity across cancers, with elevated expression levels correlating with poor prognosis in several malignancies. Immune infiltration correlation and pan-cancer single-cell transcriptomics analysis revealed a strong association between OSR2 expression and cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME). Functional enrichment analysis suggested that OSR2 may promote tumor progression through induction of epithelial-mesenchymal transition (EMT). Furthermore, OSR2 knockdown attenuated the tumor-promoting effects of CAFs, resulting in suppressed proliferation and migration of LUAD cells Conclusion: Collectively, our findings highlight the key role of OSR2 in tumor biology and tumor microenvironment regulation. OSR2 emerges as a promising prognostic biomarker and potential therapeutic target for human cancers; additionally, it may act as a reliable predictor of immunotherapy response in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.